M0 acute non lymphocytic leukemia (M0-ANLL)

Identity

Note	Stasi's criteria 30% blast cells in the bone marrow with <50% erythroblasts Cytochemical staining MPO/SSB <3% of blasts Cytochemical staining for PAS, AcP and NSE negative or weak At least one of these three immunologic markers positive : MPO, CD13, CD33, in flow cytometry or ultrastructurally Absence of cCD3, cCD22 and cCD79a
Other names	Minimally differentiated acute leukemia

Clinics and Pathology

Epidemiology	rare: 3 - 5 % of ANLL; med age 45 yrs; 20% are children; unbalanced sex ratio in the adults: 1.6 M/1F, p< 0.01
Clinics	High WBC mostly in children; frequently low Hb and platelets; organomegaly in children
Cytology	Undifferentiated blasts, cytochemistry: negative for myeloperoxydase. Positivity of at least one myeloid marker (CD13, CD33, CD65, CD117-c-KIT). Frequent expression of early progenitor markers CD34, DR; TdT in 30-40% of the cases; CD7 expression frequent in children. MPO antigen identified in about 50% of the cases.
Prognosis	Poor: CR in 50% of cases, med survival: 8 mths Poor prognosis factors: older age, high WBC, low platelets, CD10, CD14, CD15.

Cytogenetics

Cytogenetics Morphological

high percentage of complex (20%) and unbalanced karyotypes; partial or complete monosomy (5/del(5q, -7/del(7q), or rearrangements of chromosome 5 and/or 7 in 15-20%; chromosome 11 rearrangements (11q23 in particular), and chromosome 8 involvement (+8) in 10-15%; chromosome 13 involvement ( +13) in 9% ;t(9;22)(q34;q11) in 5%; near-tetraploidy in 6%; normal karyotype in 25%

Bibliography

The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors.

Costello R, Mallet F, Chambost H, Sainty D, Arnoulet C, Gastaut JA, Olive D

Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1999 ; 13 (10) : 1513-1518.

PMID 10516751

AML-M0: a review of laboratory features and proposal of new diagnostic criteria.

Stasi R, Amadori S

Blood cells, molecules & diseases. 1999 ; 25 (2) : 120-129.

PMID 10389594

Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients.

Bˆ©nˆ© MC, Bernier M, Casasnovas RO, Castoldi G, Doekharan D, van der Holt B, Knapp W, Lemez P, Ludwig WD, Matutes E, Orfao A, Schoch C, Sperling C, van't Veer MB

British journal of haematology. 2001 ; 113 (3) : 737-745.

PMID 11380465

Contributor(s)

Written	12-1999	Jean-Loup Huret
		Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Updated	05-2002	Marie Christine Bene
		Laboratoire d'Immunologie du CHU, Faculté de Médecine de Nancy, BP 184, 54500 Vandoeuvre les Nancy, France

Citation

This paper should be referenced as such :

Huret JL . M0 acute non lymphocytic leukemia (M0-ANLL). Atlas Genet Cytogenet Oncol Haematol. December 1999 . URL : http://AtlasGeneticsOncology.org/Genes/M0ANLLID1057.html

Bene MC . M0 acute non lymphocytic leukemia (M0-ANLL). Atlas Genet Cytogenet Oncol Haematol. May 2002 . URL : http://AtlasGeneticsOncology.org/Genes/M0ANLLID1057.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Sat Dec 6 18:01:29 2008

For comments and suggestions or contributions, please contact us